Retatrutide


GIP/GLP-1/glucagon triple receptor agonist

An Eli Lilly investigational triple receptor agonist of GIP, GLP-1, and glucagon receptors with Phase 3 trials in obesity producing 24% weight loss at 48 weeks.

Abstract

Retatrutide (LY3437943) is an investigational triple agonist of the GIP, GLP-1, and glucagon receptors developed by Eli Lilly and currently in Phase 3 trials for obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH). The compound builds on the GIP/GLP-1 dual agonist tirzepatide platform by adding glucagon receptor agonism, which contributes additional weight loss through hepatic energy expenditure increases and lipolytic effects. Phase 2 obesity trial results published in 2023 showed approximately 24.2 percent weight loss at 48 weeks at the highest dose, exceeding the magnitude observed with tirzepatide. The compound is not yet FDA approved; Phase 3 program is ongoing. Pharmacokinetics: weekly subcutaneous administration; half-life supports once-weekly dosing. The triple agonist class represents the current frontier of metabolic peptide development.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph